

QuaDPharma Inc. \$1,800,000 INDUCEMENT RESOLUTION

HIGHLIGHTS

Eligibility: NAICS Section - 32
 Life Science Cluster Industry

COMPANY INCENTIVES

QuaDPharma, Inc.

Quality and Delivery in Development

Approximately \$55,000 in sales tax savings

Project Title: QuaDPharma Inc.

Project Address: 11342 Main Street, Clarence, New York 14031

(Clarence School District)

Project Municipality: Newstead

SIC/NAICS: 2833/32541

Agency Request

Sales tax savings in connection with the purchase of machinery & equipment

Renovations\$250.000Manufacturing Equipment1,000,000Non-Manufacturing Equipment500,000Soft Costs60,000

Total Project Cost \$1,800,000

Company Description

QuaDPharma is a contract service provider for customers with pharmaceutical, OTC, and cosmetic products. Their focus is on semisolids (i.e. creams, lotions, ointments) and liquids. QuaDPharma provides high quality development, analytical, and manufacturing services which include:

- Analytical Testing
- Analytical Development
- ICH Stability Storage and Testing
- Formulation Development
- GMP Manufacturing of Clinical Supplies for Phase I, II, and III Studies
- Process Development
- Small Commercial Bulk Manufacturing (<100 Kg)
- Filling of Small Commercial Bulk Batches (<25,000 Units)

Project Description

QuaDPharma, Inc. has been asked to provide additional business services to their customers. These services would complement the current business offering and requires additional machinery and equipment as well as additional lab space renovations. This project would allow QuaDPharma, Inc. to diversify product lines and offer additional R&D services, as well as expand the same services into different drug dosage forms.

QuaDPharma Inc.

Project Incentives

• Approximately \$55,000 in sales tax savings

Project Benefit

The addition of 43 employees

Employment

Current: Projected (2 Years)
4 47

Project History

No Public Hearing was required since the projects benefits are below \$100,000

06/20/11 Inducement Resolution presented to Board of Directors authorizing adoption of a Negative Declaration in accordance with SEQRA.

06/20/11 Lease/Leaseback Inducement Resolution presented to Board of Directors.